The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis

Biochemical and Biophysical Research Communications

Volumn 397, Issue 2, 2010, Pages 131-135

  Li, Xia ^a   Yuan, Feng Lai ^a   Lu, Wei Guo ^a   Zhao, Yi Qing ^a   Li, Cheng Wan ^a   Li, Jian Ping ^a   Xu, Rui Sheng ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Bone erosion; Cartilage destruction; Cytokine; Interleukin 17; Rheumatoid arthritis

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; MATRIX METALLOPROTEINASE; ONCOSTATIN M; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; BONE EROSION; BONE INJURY; CARTILAGE CELL; CARTILAGE DEGENERATION; CELLULAR IMMUNITY; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; FIBROBLAST; MACROPHAGE; NONHUMAN; OSTEOCLAST; PATHOGENESIS; PATHOGENICITY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TH17 CELL; ANIMAL; ARTICULAR CARTILAGE; BONE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IMMUNOLOGY; KNEE; MOUSE; PATHOLOGY; PHYSIOLOGY;

MUS;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE AND BONES; CARTILAGE, ARTICULAR; HUMANS; INTERLEUKIN-17; KNEE JOINT; MICE; RECEPTORS, INTERLEUKIN-17;

EID: 77955488414     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.05.111     Document Type: Short Survey

References (60)

1. R.H. Straub, J.R. Kalden, Stress of different types increases the proinflammatory load in rheumatoid arthritis, Arthritis Res. Ther. 11 (2009) 114.
2. P. Santamaria, Cytokines and chemokines in autoimmune disease: an overview, Adv. Exp. Med. Biol. 520 (2003) 1-7.
3. M. Feldmann, Many cytokines are very useful therapeutic targets in disease, J. Clin. Invest. 118 (2008) 3533-3536.
4. J.C. Crispin, G.C. Tsokos, IL-17 in systemic lupus erythematosus, J. Biomed. Biotechnol. 2010 (2010) 943254.
5. S. Agarwal, R. Misra, A. Aggarwal, Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases, J. Rheumatol. 35 (2008) 515-519.
6. S. Kotake, N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, S. Ishiyama, S. Saito, K. Inoue, N. Kamatani, M.T. Gillespie, T.J. Martin, T. Suda, IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis, J. Clin. Invest. 103 (1999) 1345-1352.
7. E.M. Moran, R. Mullan, J. McCormick, M. Connolly, O. Sullivan, O. Fitzgerald, B. Bresnihan, D.J. Veale, U. Fearon, Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies, Arthritis Res. Ther. 11 (2009) R113.
8. R.L. Van Bezooijen, L. Van Der Wee-Pals, S.E. Papapoulos, C.W. Lowik, Interleukin 17 synergizes with tumour necrosis factor alpha to induce cartilage destruction in vitro, Ann. Rheum. Dis. 61 (2002) 870-876.
9. M. Chabaud, P. Garnero, J.M. Dayer, P.A. Guerne, F. Fossiez, P. Miossec, Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis, Cytokine 12 (2000) 1092-1099.
10. T. Nakashima, Y. Kobayashi, S. Yamasaki, A. Kawakami, K. Eguchi, H.M. Sasaki, H. Sakai, Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines, Biochem. Biophys. Res. Commun. 275 (2000) 768-775.
11. H. Kelchtermans, E. Schurgers, L. Geboes, T. Mitera, J. Van Damme, J. Van Snick, C. Uyttenhove, P. Matthys, Effector mechanisms of interleukin-17 in collageninduced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma, Arthritis Res. Ther. 11 (2009) R122.
12. E. Lubberts, M.I. Koenders, W.B. van den Berg, The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models, Arthritis Res. Ther. 7 (2005) 29-37.
13. J.H. Ju, M.L. Cho, Y.M. Moon, H.J. Oh, J.S. Park, J.Y. Jhun, S.Y. Min, Y.G. Cho, K.S. Park, C.H. Yoon, J.K. Min, S.H. Park, Y.C. Sung, H.Y. Kim, IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model, J. Immunol. 181 (2008) 1507-1518.
14. W.B. van den Berg, P. Miossec, IL-17 as a future therapeutic target for rheumatoid arthritis, Nat. Rev. Rheumatol. 5 (2009) 549-553.
15. E. Lubberts, M.I. Koenders, B. Oppers-Walgreen, L. van den Bersselaar, C.J. Coenen-de Roo, L.A. Joosten, W.B. van den Berg, Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion, Arthritis Rheum. 50 (2004) 650-659.
16. M.I. Koenders, J.K. Kolls, B. Oppers-Walgreen, L. van den Bersselaar, L.A. Joosten, J.R. Schurr, P. Schwarzenberger, W.B. van den Berg, E. Lubberts, Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wallinduced arthritis, Arthritis Rheum. 52 (2005) 3239-3247.
17. E. Lubberts, IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?, Cytokine 41 (2008) 84-91
18. M.I. Koenders, L.A. Joosten, W.B. van den Berg, Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis, Ann. Rheum. Dis. 65 (Suppl. 3) (2006) iii29-iii33.
19. J.K. Kolls, A. Linden, Interleukin-17 family members and inflammation, Immunity 21 (2004) 467-476.
20. R.E. Kuestner, D.W. Taft, A. Haran, C.S. Brandt, T. Brender, K. Lum, B. Harder, S. Okada, C.D. Ostrander, J.L. Kreindler, S.J. Aujla, B. Reardon, M. Moore, P. Shea, R. Schreckhise, T.R. Bukowski, S. Presnell, P. Guerra-Lewis, J. Parrish-Novak, J.L. Ellsworth, S. Jaspers, K.E. Lewis, M. Appleby, J.K. Kolls, M. Rixon, J.W. West, Z. Gao, S.D. Levin, Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F, J. Immunol. 179 (2007) 5462-5473.
21. T.A. Moseley, D.R. Haudenschild, L. Rose, A.H. Reddi, Interleukin-17 family and IL-17 receptors, Cytokine Growth Factor Rev. 14 (2003) 155-174.
22. P. Miossec, IL-17 and Th17 cells in human inflammatory diseases, Microbes Infect. 11 (2009) 625-630.
23. S.C. Liang, X.Y. Tan, D.P. Luxenberg, R. Karim, K. Dunussi-Joannopoulos, M. Collins, L.A. Fouser, Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides, J. Exp. Med. 203 (2006) 2271-2279.
24. A.F. Sheibanie, T. Khayrullina, F.F. Safadi, D. Ganea, Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis, Arthritis Rheum. 56 (2007) 2608-2619.
25. F. Fossiez, O. Djossou, P. Chomarat, L. Flores-Romo, S. Ait-Yahia, C. Maat, J.J. Pin, P. Garrone, E. Garcia, S. Saeland, D. Blanchard, C. Gaillard, B. Das Mahapatra, E. Rouvier, P. Golstein, J. Banchereau, S. Lebecque, T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines, J. Exp. Med. 183 (1996) 2593-2603.
26. J. Kennedy, D.L. Rossi, S.M. Zurawski, F. Vega Jr., R.A. Kastelein, J.L. Wagner, C.H. Hannum, A. Zlotnik, Mouse IL-17: a cytokine preferentially expressed by alpha beta TCR + CD4-CD8-T cells, J. Interferon Cytokine Res. 16 (1996) 611-617.
27. S.Y. Hwang, J.Y. Kim, K.W. Kim, M.K. Park, Y. Moon, W.U. Kim, H.Y. Kim, IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB-and PI3-kinase/Akt-dependent pathways, Arthritis Res. Ther. 6 (2004) R120-R128.
28. R.M. Onishi, S.L. Gaffen, Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease, Immunology 129 (2010) 311-321.
29. M.J. Ruddy, F. Shen, J.B. Smith, A. Sharma, S.L. Gaffen, Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment, J. Leukoc. Biol. 76 (2004) 135-144.
30. Z. Yao, W.C. Fanslow, M.F. Seldin, A.M. Rousseau, S.L. Painter, M.R. Comeau, J.I. Cohen, M.K. Spriggs, Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor, Immunity 3 (1995) 811-821.
31. Y. Hu, N. Ota, I. Peng, C.J. Refino, D.M. Danilenko, P. Caplazi, W. Ouyang, IL-17RC is required for IL-17A-and IL-17F-dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis, J. Immunol. 184 (2010) 4307-4316.
32. A. Kehlen, K. Thiele, D. Riemann, J. Langner, Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis, Clin. Exp. Immunol. 127 (2002) 539-546.
33. T. Kokubu, D.R. Haudenschild, T.A. Moseley, L. Rose, A.H. Reddi, Immunolocalization of IL-17A, IL-17B, and their receptors in chondrocytes during fracture healing, J. Histochem. Cytochem. 56 (2008) 89-95.
34. M.C. Honorati, R. Meliconi, L. Pulsatelli, S. Cane, L. Frizziero, A. Facchini, High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients, Rheumatology (Oxford) 40 (2001) 522-527.
35. M.C. Honorati, M. Bovara, L. Cattini, A. Piacentini, A. Facchini, Contribution of interleukin 17 to human cartilage degradation and synovial inflammation in osteoarthritis, Osteoarthritis Cartilage 10 (2002) 799-807.
36. R.L. Van Bezooijen, H.C. Farih-Sips, S.E. Papapoulos, C.W. Lowik, Interleukin-17: a new bone acting cytokine in vitro, J. Bone Miner. Res. 14 (1999) 1513-1521.
37. S. Kitami, H. Tanaka, T. Kawato, N. Tanabe, T. Katono-Tani, F. Zhang, N. Suzuki, Y. Yonehara, M. Maeno, IL-17A suppresses the expression of bone resorptionrelated proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells, Biochimie 92 (2010) 398-404.
38. M.O. Judex, B.M. Mueller, Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more, Am. J. Pathol. 166 (2005) 645-647.
39. S. Strobel, M. Loparic, D. Wendt, A.D. Schenk, C. Candrian, R.L. Lindberg, F. Moldovan, A. Barbero, I. Martin, Anabolic and catabolic responses of human articular chondrocytes to varying oxygen percentages, Arthritis Res. Ther. 12 (2010) R34.
40. S.B. Abramson, A. Amin, Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage, Rheumatology (Oxford) 41 (2002) 972-980.
41. P.S. Burrage, K.S. Mix, C.E. Brinckerhoff, Matrix metalloproteinases: role in arthritis, Front. Biosci. 11 (2006) 529-543.
42. L.G. Pinto, T.M. Cunha, S.M. Vieira, H.P. Lemos, W.A. Verri Jr., F.Q. Cunha, S.H. Ferreira, IL-17 mediates articular hypernociception in antigen-induced arthritis in mice, Pain 148 (2010) 247-256.
43. D. Alexander, B. Friedrich, T. Abruzzese, B. Gondolph-Zink, N. Wulker, W.K. Aicher, The active form of leflunomide, HMR1726, facilitates TNF-alpha and IL-17 induced MMP-1 and MMP-3 expression, Cell. Physiol. Biochem. 17 (2006) 69-78.
44. A. LeGrand, B. Fermor, C. Fink, D.S. Pisetsky, J.B. Weinberg, T.P. Vail, F. Guilak, Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci, Arthritis Rheum. 44 (2001) 2078-2083.
45. M. Chabaud, G. Page, P. Miossec, Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines, J. Immunol. 167 (2001) 6015-6020.
46. L.C. Grevers, P.L. van Lent, M.I. Koenders, B. Walgreen, A.W. Sloetjes, F. Nimmerjahn, J. Sjef Verbeek, W.B. van den Berg, Different amplifying mechanisms of interleukin-17 and interferon-gamma in Fcgamma receptormediated cartilage destruction in murine immune complex-mediated arthritis, Arthritis Rheum. 60 (2009) 396-407.
47. Y. Choi, J.R. Arron, M.J. Townsend, Promising bone-related therapeutic targets for rheumatoid arthritis, Nat. Rev. Rheumatol. 5 (2009) 543-548.
48. J.E. Fonseca, M.J. Santos, H. Canhao, E. Choy, Interleukin-6 as a key player in systemic inflammation and joint destruction, Autoimmun. Rev. 8 (2009) 538-542.
49. Y. Yamamoto, N. Udagawa, S. Matsuura, Y. Nakamichi, H. Horiuchi, A. Hosoya, M. Nakamura, H. Ozawa, K. Takaoka, J.M. Penninger, T. Noguchi, N. Takahashi, Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand, Endocrinology 147 (2006) 3366-3374.
50. S. Kamiya, C. Nakamura, T. Fukawa, K. Ono, T. Ohwaki, T. Yoshimoto, S. Wada, Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation, J. Bone Miner. Metab. 25 (2007) 277-285.
51. T. Yago, Y. Nanke, N. Ichikawa, T. Kobashigawa, M. Mogi, N. Kamatani, S. Kotake, IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17, J. Cell. Biochem. 108 (2009) 947-955.
52. T. Yago, Y. Nanke, M. Kawamoto, T. Furuya, T. Kobashigawa, N. Kamatani, S. Kotake, IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats, Arthritis Res. Ther. 9 (2007) R96.
53. E. Lubberts, L. van den Bersselaar, B. Oppers-Walgreen, P. Schwarzenberger, C.J. Coenen-de Roo, J.K. Kolls, L.A. Joosten, W.B. van den Berg, IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance, J. Immunol. 170 (2003) 2655-2662.
54. M. Chabaud, E. Lubberts, L. Joosten, W. van Den Berg, P. Miossec, IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis, Arthritis Res. 3 (2001) 168-177.
55. M.I. Koenders, E. Lubberts, B. Oppers-Walgreen, L. van den Bersselaar, M.M. Helsen, F.E. Di Padova, A.M. Boots, H. Gram, L.A. Joosten, W.B. van den Berg, Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1, Am. J. Pathol. 167 (2005) 141-149.
56. E. Lubberts, P. Schwarzenberger, W. Huang, J.R. Schurr, J.J. Peschon, W.B. van den Berg, J.K. Kolls, Requirement of IL-17 receptor signaling in radiationresistant cells in the joint for full progression of destructive synovitis, J. Immunol. 175 (2005) 3360-3368.
57. K.A. Bush, K.M. Farmer, J.S. Walker, B.W. Kirkham, Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein, Arthritis Rheum. 46 (2002) 802-805.
58. M. Chabaud, P. Miossec, The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model, Arthritis Rheum. 44 (2001) 1293-1303.
59. E.M. Colin, P.S. Asmawidjaja, J.P. van Hamburg, A.M. Mus, M. van Driel, J.M. Hazes, J.P. van Leeuwen, E. Lubberts, 1,25-Dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis, Arthritis Rheum. 62 (2010) 132-142.
60. E. Lubberts, Th17 cytokines and arthritis, Semin. Immunopathol. 32 (2010) 43-53.